The price-to-earnings ratio for Corcept Therapeutics Inc (NASDAQ: CORT) is above average at 24.60x. The 36-month beta value for CORT is also noteworthy at 0.49. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”
The public float for CORT is 89.19M, and at present, short sellers hold a 23.68% of that float. The average trading volume of CORT on May 01, 2024 was 1.12M shares.
CORT) stock’s latest price update
The stock of Corcept Therapeutics Inc (NASDAQ: CORT) has decreased by -0.21 when compared to last closing price of 23.37. Despite this, the company has experienced a 1.39% gain in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-04-23 that Corcept (CORT) reports positive data from the open-label portion of the phase III GRACE study evaluating relacorilant for treating patients with Cushing’s syndrome.
CORT’s Market Performance
Corcept Therapeutics Inc (CORT) has experienced a 1.39% rise in stock performance for the past week, with a -9.40% drop in the past month, and a 6.63% rise in the past quarter. The volatility ratio for the week is 3.89%, and the volatility levels for the past 30 days are at 4.18% for CORT. The simple moving average for the last 20 days is -1.48% for CORT stock, with a simple moving average of -12.24% for the last 200 days.
Analysts’ Opinion of CORT
Many brokerage firms have already submitted their reports for CORT stocks, with Truist repeating the rating for CORT by listing it as a “Buy.” The predicted price for CORT in the upcoming period, according to Truist is $38 based on the research report published on November 06, 2023 of the previous year 2023.
SVB Securities, on the other hand, stated in their research note that they expect to see CORT reach a price target of $25. The rating they have provided for CORT stocks is “Market Perform” according to the report published on April 11th, 2023.
Piper Sandler gave a rating of “Overweight” to CORT, setting the target price at $27 in the report published on April 04th of the previous year.
CORT Trading at -1.93% from the 50-Day Moving Average
After a stumble in the market that brought CORT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -31.96% of loss for the given period.
Volatility was left at 4.18%, however, over the last 30 days, the volatility rate increased by 3.89%, as shares sank -8.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +2.69% upper at present.
During the last 5 trading sessions, CORT rose by +1.39%, which changed the moving average for the period of 200-days by +2.19% in comparison to the 20-day moving average, which settled at $23.57. In addition, Corcept Therapeutics Inc saw -28.20% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CORT starting from Lyon Joseph Douglas, who sale 5,443 shares at the price of $26.00 back on Apr 04 ’24. After this action, Lyon Joseph Douglas now owns 7,314 shares of Corcept Therapeutics Inc, valued at $141,524 using the latest closing price.
Swisher Daniel N JR, the Director of Corcept Therapeutics Inc, sale 2,200 shares at $25.30 during a trade that took place back on Apr 01 ’24, which means that Swisher Daniel N JR is holding 0 shares at $55,660 based on the most recent closing price.
Stock Fundamentals for CORT
Current profitability levels for the company are sitting at:
- 0.22 for the present operating margin
- 0.99 for the gross margin
The net margin for Corcept Therapeutics Inc stands at 0.22. The total capital return value is set at 0.21. Equity return is now at value 20.92, with 17.51 for asset returns.
Based on Corcept Therapeutics Inc (CORT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at 841.32.
Currently, EBITDA for the company is 109.64 million with net debt to EBITDA at -1.24. When we switch over and look at the enterprise to sales, we see a ratio of 4.72. The receivables turnover for the company is 8.75for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.39.
Conclusion
In summary, Corcept Therapeutics Inc (CORT) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
